CLDX Overview

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Wall Street analysts forecast CLDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLDX is55.00 USD with a low forecast of 24.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Celldex Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

Celldex Therapeutics Inc. EPS for the last quarter amounts to -1.01 USD, increased 57.81 % YoY.

Celldex Therapeutics Inc (CLDX) has 186 emplpoyees as of January 29 2026.

Today CLDX has the market capitalization of 2.00B USD.